Journal of Antimicrobial Chemotherapy · 2019 · 22 citations · 40 references
MedicineMicrobiologyPharmacologyImmunopharmacologyMedical MicrobiologyMycologyAntifungal AgentsAntifungal PharmacologyAntifungal PharmacotherapyAntifungal TherapyFungal InfectionsFungal PathogenesisAntagonistic InteractionsFungal Infection TreatmentFungal Infections In Immunocompromised HostsIn-vitro CharacterizationMtor InhibitionMtor SignalingMucormycosis PharmacotherapyMucormycosis Treatment
OBJECTIVES: To evaluate the in vitro interactions of isavuconazole with immune suppressors (tacrolimus, cyclosporin A or sirolimus) against 30 Mucorales isolates belonging to the most common species responsible for mucormycosis in humans (Rhizopus arrhizus, Rhizopus delemar, Rhizopus microsporus, Lichtheimia corymbifera, Lichtheimia ramosa, Mucor circinelloides and Rhizomucor pusillus). METHODS: In vitro interaction was evaluated by a microdilution chequerboard technique. RESULTS: Combination of isavuconazole with tacrolimus, cyclosporin A or sirolimus, was synergistic for 50%, 46% and 7% of the isolates, respectively. Antagonistic interaction was observed for 4% of the isolates for the combination with cyclosporin A (one R. arrhizus isolate) and for 32% of the isolates for the combination with sirolimus (six R. arrhizus isolates and three R. pusillus isolates). CONCLUSIONS: These in vitro data show that calcineurin inhibitors are more likely than inhibitors of the mTOR pathway to enhance the activity of isavuconazole against Mucorales. These in vitro results warrant further animal experiments.
40
Peter G. Pappas, Barbara D. Alexander, David R. Andes et al. · Clinical Infectious Diseases · 2010 · 1.6K citations · Full text
Johan Maertens, Issam Raad, Kieren A. Marr et al. · The Lancet · 2015 · 972 citations